Home »

Amunix Announces Update to Licensing Agreement With Janssen for Its Proprietary XTEN Technology

MOUNTAIN VIEW, CA — (Marketwired) — 08/14/13 — Amunix Operating Inc. (Amunix), today announced that an option for an additional product has been exercised under its worldwide research collaboration and licensing agreement with Janssen Biotech, Inc. (Janssen). Under the exercised option, Amunix will combine its XTEN half-life extension technology with a lead therapeutic molecule selected by Janssen, which will be responsible for all preclinical and clinical development as well as the commerci

Preclinical Data From Biogen Idec-Amunix Partnership Presented at ISTH Congress

Presentations Feature Amunix XTEN Half-Life Extension Technology for FVIII and FVIIa

Analytics

© 2020 88Finance. All Rights Reserved. Log in - Copyright by LayerMedia


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de